Table 1.
Clinical and pathological features of the study participants from the MCCS and TCGA
| Sample characteristics | MCCS N = 130 | TCGA N = 168 | P value |
|---|---|---|---|
| Median age at diagnosis (years), interquartile range | 65 [25%; 58] | 62 [25%; 51] | 0.02 |
| < 50 years (n, %) | 6 (5) | 35 (21) | 0.0002 |
| 50–60 years (n, %) | 39 (30) | 35 (21) | |
| 60+ years (n, %) | 85 (65) | 98 (58) | |
| Year of diagnosis (n, %) | |||
| 1992–1996 | 18 (14) | 0 (0) | 4.4 × 10−30 |
| 1997–2001 | 47 (36) | 4 (2) | |
| 2002–2005 | 36 (28) | 15 (9) | |
| 2006 and later | 29 (22) | 147 (86) | |
| Missing | 0 (0) | 2 (1) | |
| Overall deaths (n, %) | 37 (28) | 14 (8) | 4.7 × 10−06 |
| Median follow-up time (years) | 13 | 2 | 2.2 × 10−16 |
| Tumour grade (n, %) | |||
| Grade I | 13 (10) | NA | NA |
| Grade II | 80 (61) | NA | |
| Grade III | 17 (13) | NA | |
| Missing | 20 (15) | NA | |
| Tumour stage (n, %) | |||
| 1A/1B | 65 (50) | 20 (12) | 1.9 × 10−12 |
| 2A/2B | 48 (37) | 92 (55) | |
| 3A/3C/4 | 17 (13) | 55 (33) | |
| Missing | 0 (0) | 1 (0.5) | |
| Tumour ER expression (n, %) | |||
| Positive | 121 (93) | 157 (93) | 0.32 |
| Negative | 8 (6) | 6 (4) | |
| Missing | 1 (1) | 5 (3) | |
| Tumour PR expression (n, %) | |||
| Positive | 94 (72) | 140 (83) | 0.004 |
| Negative | 35 (27) | 22 (13) | |
| Missing | 1 (1) | 6 (4) | |
| Tumour HER2 expression (n, %) | |||
| Positive | 11 (8) | 21 (13) | 1.5 × 10−5 |
| Negative | 92 (71) | 84 (50) | |
| Equivocal | 5 (4) | 35 (21) | |
| Missing | 22 (17) | 28 (17) | |
ER oestrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2
P = values are for chi-square tests and T-tests for categorical and continuous variables, respectively